Centers | ||
Therapeutic Accelerator Program (TAP) | test | Weccome Centre for Anti-Infectives Research |
Test |
sfgd |
WCAIR brings together the Drug Discovery Unit (DDU) , the Mode of Action group and the Parasitology research groups. With the daily interactions of these groups, parasitology and drug discovery can work together in synergy. This empowers us to create... Read more |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all |
No EVENTS for listing |
No Job Posts |


